European Lung Cancer Congress 2024
![ELCC2023_PosterSession_02](/var/esmo/storage/images/media/esmo-daily-reporter/images/elcc-24/coverage/elcc2023_postersession_02/18966937-1-eng-GB/elcc2023_postersession_02_i770.jpg)
A study shows correlation between fatty acids intake and response to immunotherapy
Dietary regimens may alter the microbiome composition, increasing bacteria with a beneficial immunogenic effect
![ELCC2024_Delegates_Venue_02](/var/esmo/storage/images/media/esmo-daily-reporter/images/elcc-24/coverage/elcc2024_delegates_venue_02/18939262-1-eng-GB/elcc2024_delegates_venue_02_i770.jpg)
Concomitant immunotherapy plus chemoradiotherapy does not improve outcomes in advanced lung cancer
A study reports no significant survival benefits with the concurrent treatment with durvalumab in patients with unresectable stage III NSCLC
![ELCC2024_PosterSession](/var/esmo/storage/images/media/esmo-daily-reporter/images/elcc-24/coverage/elcc2024_postersession/18942269-1-eng-GB/elcc2024_postersession_i770.jpg)
Are ADCs in lung cancer living up to expectations?
High rates of adverse events in the experimental setting seem to limit the potential of antibody–drug conjugates for patients with NSCLC
![Maximilian Diehn](/var/esmo/storage/images/media/esmo-daily-reporter/images/portraits/maximilian-diehn/18938828-1-eng-GB/maximilian-diehn_i770.png)
Incorporating ctDNA into clinical trial design
ctDNA offers immense possibilities for improving the management of early-stage lung cancer and the area is primed for new trials to test this approach in the context of minimal residual disease
![Yu-Ju Chen](/var/esmo/storage/images/media/esmo-daily-reporter/images/portraits/yu-ju-chen/18938822-1-eng-GB/yu-ju-chen_i770.jpg)
How can proteomics aid the study of lung cancer in never smokers?
Personalised proteogenomics has the power to transform the identification, staging and management of NSCLC in never smokers
![ELCC2024_Piotrowska](/var/esmo/storage/images/media/esmo-daily-reporter/images/elcc-24/coverage/elcc2024_piotrowska/18941117-1-eng-GB/elcc2024_piotrowska_i770.jpg)
Post-progression data confirm the benefits of novel combinations for EGFR-mutated NSCLC
Analyses of FLAURA2, MARIPOSA and MARIPOSA-2 trials provide further guidance on treatment choices for advanced lung cancer, but questions remain about optimal sequencing
![ELCC2024_Audience_03](/var/esmo/storage/images/media/esmo-daily-reporter/images/elcc-24/coverage/elcc2024_audience_03/18940616-1-eng-GB/elcc2024_audience_03_i770.jpg)
Could subcutaneous administration become the standard for immunotherapy?
Two studies add further evidence of the advantages of this route for delivering immune checkpoint inhibitors for patients and healthcare sustainability
![ELCC2024_Audience_01](/var/esmo/storage/images/media/esmo-daily-reporter/images/elcc-24/coverage/elcc2024_audience_01/18940309-1-eng-GB/elcc2024_audience_01_i770.jpg)
Promising efficacy data reported for a targeted agent harbouring a MET alteration in NSCLC
Efficacy for savolitinib in patients with MET exon 14 alterations is in line with that for other MET tyrosine kinase inhibitors, but safety profile is different
![Editorial_Lung](/var/esmo/storage/images/media/esmo-daily-reporter/images/editorials/editorial_lung/18319774-1-eng-GB/editorial_lung_i770.jpg)
Europe cannot afford to wait any longer for cleaner air
Despite recent progress, lung cancer remains deadly and difficult to treat — and preventable, to a much greater extent with the right actions to improve the quality of the air we breathe
![How ‘precise’ has lung cancer treatment become?](/var/esmo/storage/images/esmo-daily-reporter/european-lung-cancer-congress-2024/highlights-from-elcc-2024/how-precise-has-lung-cancer-treatment-become/18933293-3-eng-GB/how-precise-has-lung-cancer-treatment-become_i770.jpg)
How ‘precise’ has lung cancer treatment become?
Precision oncology is evolving from advanced to early-stage NSCLC, highlights Prof. Enriqueta Felip in her Heine H. Hansen Award lecture at ELCC 2024